Magnetically enhanced protection of bone marrow from beta particles emitted by bone-seeking radionuclides: Theory of application

Raymond R. Ravlman, Richard L. Wahl

Research output: Contribution to journalArticle

Abstract

Utilization of radiopharmaceuticals that directly target radioactivity to tumors for treatment has a great deal of promise. Ideally, lethal doses of radiation could be delivered precisely to areas of disease, while, for the most part, sparing normal tissues. This potential, however, has not yet been fully realized. Current limitations of this approach are low tumor uptake of radiopharmaceuticals and dose-limiting radiotoxicity. In an effort to offset low uptake, radionuclides that emit high average-energy electrons have been proposed. Unfortunately, use of these radionuclides increases myelosuppression on a per decay basis. In order to allow for the utilization of high doses of this class of high-energy beta emitters, we propose the application of a strong static homogeneous magnetic field to constrain the beta particles. Monte Carlo computer simulations indicate that application of a 10 T magnetic field can decrease the total radiation dose from bone-avid tracers to marrow located in shafts of human long bones by 14%. More significantly, however, the penetration depth of high-energy electrons from the bone surface into the marrow can be reduced by up to 74.6%. Preservation of marrow in areas distal to the bone has previously been shown to facilitate relatively rapid recovery from pancytopenia produced by radiation damage to trabecular marrow (without marrow transplantation). Magnetically enhanced protection of bone marrow, therefore, may allow administered doses of high-energy beta-emitting radionuclides to be increased. By raising the limits on injected quantities of such highly ionizing radionuclides, amounts of the radiation dose absorbed by both soft and calcified tissue tumors will be increased, compared to conventional treatments. Hence, it is possible that this technique will, in part, aid in the realization of the promise of radionuclide therapy by permitting the delivery of therapeutic levels of radiation exposure to tumors.

Original languageEnglish (US)
Pages (from-to)1285-1292
Number of pages8
JournalMedical Physics
Volume22
Issue number8
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Beta Particles
Radioisotopes
Bone Marrow
Bone and Bones
Radiation
Radiopharmaceuticals
Magnetic Fields
Neoplasms
Electrons
Pancytopenia
Computer Simulation
Radioactivity
Transplantation
Therapeutics

Keywords

  • bone marrow dosimetry
  • magnetic fields radionuclide therapy

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging

Cite this

Magnetically enhanced protection of bone marrow from beta particles emitted by bone-seeking radionuclides : Theory of application. / Ravlman, Raymond R.; Wahl, Richard L.

In: Medical Physics, Vol. 22, No. 8, 1995, p. 1285-1292.

Research output: Contribution to journalArticle

@article{72b20e51de1c4ca4b5f1090e46ccb6d5,
title = "Magnetically enhanced protection of bone marrow from beta particles emitted by bone-seeking radionuclides: Theory of application",
abstract = "Utilization of radiopharmaceuticals that directly target radioactivity to tumors for treatment has a great deal of promise. Ideally, lethal doses of radiation could be delivered precisely to areas of disease, while, for the most part, sparing normal tissues. This potential, however, has not yet been fully realized. Current limitations of this approach are low tumor uptake of radiopharmaceuticals and dose-limiting radiotoxicity. In an effort to offset low uptake, radionuclides that emit high average-energy electrons have been proposed. Unfortunately, use of these radionuclides increases myelosuppression on a per decay basis. In order to allow for the utilization of high doses of this class of high-energy beta emitters, we propose the application of a strong static homogeneous magnetic field to constrain the beta particles. Monte Carlo computer simulations indicate that application of a 10 T magnetic field can decrease the total radiation dose from bone-avid tracers to marrow located in shafts of human long bones by 14{\%}. More significantly, however, the penetration depth of high-energy electrons from the bone surface into the marrow can be reduced by up to 74.6{\%}. Preservation of marrow in areas distal to the bone has previously been shown to facilitate relatively rapid recovery from pancytopenia produced by radiation damage to trabecular marrow (without marrow transplantation). Magnetically enhanced protection of bone marrow, therefore, may allow administered doses of high-energy beta-emitting radionuclides to be increased. By raising the limits on injected quantities of such highly ionizing radionuclides, amounts of the radiation dose absorbed by both soft and calcified tissue tumors will be increased, compared to conventional treatments. Hence, it is possible that this technique will, in part, aid in the realization of the promise of radionuclide therapy by permitting the delivery of therapeutic levels of radiation exposure to tumors.",
keywords = "bone marrow dosimetry, magnetic fields radionuclide therapy",
author = "Ravlman, {Raymond R.} and Wahl, {Richard L.}",
year = "1995",
doi = "10.1118/1.597513",
language = "English (US)",
volume = "22",
pages = "1285--1292",
journal = "Medical Physics",
issn = "0094-2405",
publisher = "AAPM - American Association of Physicists in Medicine",
number = "8",

}

TY - JOUR

T1 - Magnetically enhanced protection of bone marrow from beta particles emitted by bone-seeking radionuclides

T2 - Theory of application

AU - Ravlman, Raymond R.

AU - Wahl, Richard L.

PY - 1995

Y1 - 1995

N2 - Utilization of radiopharmaceuticals that directly target radioactivity to tumors for treatment has a great deal of promise. Ideally, lethal doses of radiation could be delivered precisely to areas of disease, while, for the most part, sparing normal tissues. This potential, however, has not yet been fully realized. Current limitations of this approach are low tumor uptake of radiopharmaceuticals and dose-limiting radiotoxicity. In an effort to offset low uptake, radionuclides that emit high average-energy electrons have been proposed. Unfortunately, use of these radionuclides increases myelosuppression on a per decay basis. In order to allow for the utilization of high doses of this class of high-energy beta emitters, we propose the application of a strong static homogeneous magnetic field to constrain the beta particles. Monte Carlo computer simulations indicate that application of a 10 T magnetic field can decrease the total radiation dose from bone-avid tracers to marrow located in shafts of human long bones by 14%. More significantly, however, the penetration depth of high-energy electrons from the bone surface into the marrow can be reduced by up to 74.6%. Preservation of marrow in areas distal to the bone has previously been shown to facilitate relatively rapid recovery from pancytopenia produced by radiation damage to trabecular marrow (without marrow transplantation). Magnetically enhanced protection of bone marrow, therefore, may allow administered doses of high-energy beta-emitting radionuclides to be increased. By raising the limits on injected quantities of such highly ionizing radionuclides, amounts of the radiation dose absorbed by both soft and calcified tissue tumors will be increased, compared to conventional treatments. Hence, it is possible that this technique will, in part, aid in the realization of the promise of radionuclide therapy by permitting the delivery of therapeutic levels of radiation exposure to tumors.

AB - Utilization of radiopharmaceuticals that directly target radioactivity to tumors for treatment has a great deal of promise. Ideally, lethal doses of radiation could be delivered precisely to areas of disease, while, for the most part, sparing normal tissues. This potential, however, has not yet been fully realized. Current limitations of this approach are low tumor uptake of radiopharmaceuticals and dose-limiting radiotoxicity. In an effort to offset low uptake, radionuclides that emit high average-energy electrons have been proposed. Unfortunately, use of these radionuclides increases myelosuppression on a per decay basis. In order to allow for the utilization of high doses of this class of high-energy beta emitters, we propose the application of a strong static homogeneous magnetic field to constrain the beta particles. Monte Carlo computer simulations indicate that application of a 10 T magnetic field can decrease the total radiation dose from bone-avid tracers to marrow located in shafts of human long bones by 14%. More significantly, however, the penetration depth of high-energy electrons from the bone surface into the marrow can be reduced by up to 74.6%. Preservation of marrow in areas distal to the bone has previously been shown to facilitate relatively rapid recovery from pancytopenia produced by radiation damage to trabecular marrow (without marrow transplantation). Magnetically enhanced protection of bone marrow, therefore, may allow administered doses of high-energy beta-emitting radionuclides to be increased. By raising the limits on injected quantities of such highly ionizing radionuclides, amounts of the radiation dose absorbed by both soft and calcified tissue tumors will be increased, compared to conventional treatments. Hence, it is possible that this technique will, in part, aid in the realization of the promise of radionuclide therapy by permitting the delivery of therapeutic levels of radiation exposure to tumors.

KW - bone marrow dosimetry

KW - magnetic fields radionuclide therapy

UR - http://www.scopus.com/inward/record.url?scp=0029146820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029146820&partnerID=8YFLogxK

U2 - 10.1118/1.597513

DO - 10.1118/1.597513

M3 - Article

C2 - 7476715

AN - SCOPUS:0029146820

VL - 22

SP - 1285

EP - 1292

JO - Medical Physics

JF - Medical Physics

SN - 0094-2405

IS - 8

ER -